The reverse stock split has reduced the number of issued and outstanding ordinary shares from 254,574,913 pre-split to approximately 31,821,865 post-split.

The reverse split does not impact any shareholder’s percentage ownership of the Company or voting power, except for minimal effects resulting from the treatment of fractional shares. No fractional ordinary shares will be issued as a result of the reverse split as any fractional ordinary shares resulting from the reverse split will be rounded up to the nearest whole share on a per shareholder basis.

There can be no assurance that the Company will satisfy other applicable requirements for listing its ordinary shares on Nasdaq or that the Company’s application to uplist its ordinary shares will be approved.Īs a result of the reverse stock split, every eight (8) shares of the Company’s issued and outstanding ordinary shares have been automatically combined into one (1) issued and outstanding ordinary shares. The reverse stock split is an action intended to meet the stock price requirement for official listing on NASDAQ. The Company implemented the reverse stock split in connection with its previously announced plan to uplist the Company’s ordinary shares to the Nasdaq Capital Market. Trading in the ordinary shares on a split-adjusted basis will continue on TASE under the symbol “ICCM”, however, the security has been assigned with a new CUSIP number. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, yesterday announced that it has implemented an 8-for-1 reverse split of its ordinary shares effective prior to the opening of market trading on Sunday, August 8, 2021. CAESAREA, Israel, AugIceCure Medical Ltd.

When was nvda stock split announced